In the invention, phytochromes are activated in focuses such as tumors, vascular patches and
skin diseases, in a fixed-point and fixed-quantity way by a specific means through the utilization of the specific affinity action of the phytochromes on the focuses, the
decomposition reaction of H2O2 is catalyzed by the phytochromes to generate <1>O2, and the
apoptosis or the
necrosis of
pathological cells is caused, thereby achieving the purpose of treating the diseases. A corresponding serial novel
drug is screened, developed and used for CDT (Chemodynamic Therapy) or RCDT (Radiochemodynamic Therapy). The invention relates to the serial novel
drug which is used for CDT and RCDT. The serial novel
drug can catalyze the
chemical reaction of decomposing the H2O2 to generate the <1>O2, does not have obvious
side effect on the normal tissues and organs of a
human body, and meanwhile, has the capability of affiliating the focuses. The phytochromes are used as a catalyst, and the acting mechanism, the usage, the
therapeutic effect and the like of the phytochromes are completely different from those of traditional photo-dynamic therapy.
Oxygen and visual light are not needed, and a completely independent novel drug series can be formed.